U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07172516) titled 'A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)' on Sept. 08.
Brief Summary: X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).
Study Start Date: Aug. 08
Study Type: INTERVENTIONAL
Condition:
Bipolar Disorder
Bipolar Depression
Bipolar I Disorder
Bipolar II Disorder
Intervention:
DRUG: Azetukalner
Azetukalner 20 mg taken orally once ...